Highlights Herantis Pharma Oyj

Equities

HRTIS

FI4000087861

Market Closed - Nasdaq Helsinki Other stock markets 15:53:33 10/05/2024 BST			5-day change	1st Jan Change
1.45 ^EUR	+2.11%		+2.47%	-7.94%

03-06	Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-06	Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
Herantis Pharma Plc Announces Positive Topline Data from Phase 1a Clinical Trial of HER-096	25/10/23	CI
Herantis Pharma Oyj Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23	CI
Herantis Pharma plc Announces First Healthy Volunteers Dosed in the Part 2 of the Her-096 Phase 1A Clinical Study	22/08/23	CI
Herantis Pharma Plc Announces Start of Recruitment of Healthy Volunteers for Part 2 of the Ongoing Phase 1a Clinical Study of HER-096	04/07/23	CI
Herantis Pharma Oyj Announces First Healthy Volunteer Dosed in the Phase 1a Clinical Study for the Parkinson's Disease Drug Candidate, HER-096	19/04/23	CI
Herantis Pharma plc Announces Approval of Clinical Trial Application for A Phase 1 Study for HER-096	20/02/23	CI
Herantis Pharma Oyj Announces Submission of A Clinical Trial Application for A Phase 1 Study for HER-096	19/12/22	CI
Finland's Herantis Pharma Applies to Cancel Secondary Listing on Nasdaq First North Growth Market Sweden	01/12/22	MT
Herantis Pharma Oyj Reports Earnings Results for the Half Year Ended June 30, 2022	24/08/22	CI
Herantis Pharma Oyj Announces Successful HER-096 Initial Results with Blood-Brain Barrier Penetration in Dogs	28/04/22	CI
Herantis Pharma Plc Announces Successful HER-096 Initial Results with Nanoform Technology	24/03/22	CI
Herantis Pharma Oyj : Plc Annual Report 2021	22/03/22	PU
Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2021	03/03/22	CI
Herantis to Focus on HER-096	20/01/22	CI
Herantis Pharma Announces Poster and Presentation at MDS Virtual Congress 2021	17/09/21	CI
Herantis Pharma Announces Successful rhCDNF Results With Nanoform Technology	09/09/21	CI
Herantis Pharma Oyj Reports Earnings Results for the Half Year Ended June 30, 2021	26/08/21	CI
Herantis Pharma Announces xCDNF Preclinical Candidate Selection	31/05/21	CI
Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2020	03/03/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Herantis Pharma Oyj

Equities

HRTIS

FI4000087861

Highlights

Filters